AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

2.060

-0.030-1.44%

Volume:5.89M

Turnover:12.24M

Market Cap:2.61B

PE:-14.13

High:2.130

Open:2.100

Low:2.035

Close:2.090

Loading ...

Overview Company News Filings

Mesoblast Ltd - Hy Loss Attributable $47.9 Mln

THOMSON REUTERS

Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Mesoblast Financial Results and Corporate Update Webcast

Mesoblast Ltd expected to post a loss of 14 cents a share - Earnings Preview

DR. Gregory George Md Phd Joins Mesoblast Board

THOMSON REUTERS

Dr. Gregory George MD PhD Joins Mesoblast Board

3 ASX Stocks Estimated To Be 31.3% To 41.2% Below Intrinsic Value

Simply Wall St.

Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings

THOMSON REUTERS

Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value

Simply Wall St.

Cynata Therapeutics' Drug Candidate Could See Pricing Revision Following Mesoblast's Ryoncil Launch, Euroz Hartleys Says

MT Newswires Live

Is Mesoblast Limited (MESO) the Best Long Term ASX Stock to Buy Now?

Mesoblast Price Target Raised to $24.00/Share From $15.00 by Piper Sandler

Mesoblast's Largest Shareholder Raises Stake to Over 19%; Mesoblast Shares Up 3%

MT Newswires Live

5 ASX All Ords shares upgraded to 'strong buy' consensus ratings

BRIEF-Mesoblast Ltd Files Prospectus Relates To Offer And Sale Of Up To 34.7 Million Ordinary Shares

Mesoblast Ltd Files Prospectus Relates to Offer and Sale From Time to Time by the Shareholders of up to 34.7 Mln Ordinary Shares

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/MSB.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MSB.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.06,"timestamp":1741583520000,"preClose":2.09,"halted":0,"volume":5890076,"delay":0,"changeRate":-0.014354,"change":-0.03,"floatShares":734902424,"shares":1268947688,"eps":-0.14583923,"lyrEps":-0.140904,"pbRate":3.59,"amount":12244880,"amplitude":0.045455,"volumeRatio":0.458514,"dividePrice":0,"prevYearClose":3.1,"fiveDayClose":2.51,"twentyDayClose":3.02},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":734902424,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.140904,"volumeRatio":0.458514,"shares":1268947688,"dividePrice":0,"high":2.13,"amplitude":0.045455,"preClose":2.09,"low":2.035,"week52Low":0.315,"pbRate":"3.59","psRate":"291.66","week52High":3.37,"institutionHeld":0,"latestPrice":2.06,"committee":0.205824,"eps":-0.14583922799086363,"divideRate":0,"volume":5890076,"delay":0,"ttmEps":-0.14583922799086363,"open":2.1,"prevYearClose":3.1,"prevWeekClose":2.09,"prevMonthClose":2.52,"prevQuarterClose":3.1,"fiveDayClose":2.51,"twentyDayClose":3.02,"sixtyDayClose":1.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514689388","title":"Mesoblast Ltd - Hy Loss Attributable $47.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514689388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514689388?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:39","pubTimestamp":1740605952,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1XU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7508","MESO","BK7501","BK7067","BK4139"],"gpt_icon":0},{"id":"2514868686","title":"Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2514868686","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514868686?lang=en_us&edition=fundamental","pubTime":"2025-02-26 22:55","pubTimestamp":1740581713,"startTime":"0","endTime":"0","summary":"A downtrend has been apparent in Mesoblast Limited  lately. While the stock has lost 10.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the stock. On the fundamental side, strong agreement among Wall Street analysts in raising earnings estimates for this company enhances its prospects of a trend reversal.Understanding Hammer Chart and the Technique to Trade It. If this is not enough, you should note that MESO currently has a Zacks Rank #2 , which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS su","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-limited-meso-could-support-145513668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MESO","MSB.AU"],"gpt_icon":0},{"id":"2514023959","title":"Mesoblast Financial Results and Corporate Update Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2514023959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514023959?lang=en_us&edition=fundamental","pubTime":"2025-02-26 07:13","pubTimestamp":1740525180,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 25, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the half year ended December 31, 2024.The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com. About Mesoblast Mesoblast  is a world leader in developing allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.Mesoblast’s RYONCIL  for the treatment of steroid-refractory acute graft versus host disease  in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-financial-results-corporate-webcast-231300053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MESO","BK4575","BK4006","MSB","BK4150","MSC","BK4139","MSB.AU"],"gpt_icon":0},{"id":"2514062464","title":"Mesoblast Ltd  expected to post a loss of 14 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2514062464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514062464?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:12","pubTimestamp":1740481943,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd  expected to post a loss of14cents a share - Earnings Preview Mesoblast Ltd MESO.OQ, MESO.O is expected to report resultson February 27 for the period ending September 30 2024The Melbour","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nL5N3PG0VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","MSB.AU"],"gpt_icon":0},{"id":"2513667287","title":"DR. Gregory George Md Phd Joins Mesoblast Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2513667287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513667287?lang=en_us&edition=fundamental","pubTime":"2025-02-24 07:33","pubTimestamp":1740353633,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nTUA39FYLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2513769339","title":"Dr. Gregory George MD PhD Joins Mesoblast Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2513769339","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513769339?lang=en_us&edition=fundamental","pubTime":"2025-02-24 07:33","pubTimestamp":1740353580,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 23, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast’s largest shareholder, to its Board of Directors.Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization.Mesoblast Founder and Chief Executive Dr. Silviu Itescu said, “Greg’s unique operational skills and insights will provide tremendous value as Mesoblast transitions to become an efficient commercial organization.”Mesoblast is committed to developing additional cell therapies for distinct","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dr-gregory-george-md-phd-233300998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7501","MESO","BK4575","MMAT","MSB","BK7508","BK4150","MD","BK4196","BK7067","BK4139","MSC","BK4141","BK4006","MSB.AU"],"gpt_icon":0},{"id":"2512364851","title":"3 ASX Stocks Estimated To Be 31.3% To 41.2% Below Intrinsic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2512364851","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512364851?lang=en_us&edition=fundamental","pubTime":"2025-02-18 16:02","pubTimestamp":1739865741,"startTime":"0","endTime":"0","summary":"The Australian market is currently navigating a complex landscape, with the Reserve Bank of Australia's recent interest rate cut and mixed sector performances highlighting the challenges and opportunities for investors. In this environment, identifying undervalued stocks can be particularly rewarding, as they may offer potential growth when their intrinsic value is recognized by the market.Top 10 Undervalued Stocks Based On Cash Flows In Australia. Audinate Group is trading at A$10.41, significantly undervalued compared to its estimated fair value of A$16.03, suggesting potential upside based on discounted cash flow analysis. Despite a challenging financial period with a net loss of A$2.21 million and reduced profit margins, earnings are forecast to grow substantially at 51% annually, outpacing the Australian market's growth rate. However, return on equity remains low at 6.8%, indicating room for improvement in profitability metrics.PolyNovo is trading at A$1.92, below its fair value e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-stocks-estimated-31-080221754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["WHC.AU","ALX.AU","SYL.AU","IDX.AU","BK7503","AD8.AU","BK7507","PNV.AU","IEL.AU","BK7501","BK7126","BK7132","MLG.AU","BK7110","BK7073","SFR.AU","BK7064","BK7055","RDY.AU","BK7090","BK7506","XJO.AU","BK7508","XKO.AU","BK7083","BK7067","BK7095","BK7094","MAD.AU","XAO.AU","ALC.AU","MSB.AU","BK7124","BK7016"],"gpt_icon":0},{"id":"2511019645","title":"Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2511019645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511019645?lang=en_us&edition=fundamental","pubTime":"2025-02-14 07:37","pubTimestamp":1739489856,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nTUA8M8KDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","MSB.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2510342445","title":"Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2510342445","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510342445?lang=en_us&edition=fundamental","pubTime":"2025-02-12 16:02","pubTimestamp":1739347352,"startTime":"0","endTime":"0","summary":"The Australian market has recently shown positive momentum, with the ASX200 closing up 0.6% at 8,535 points, driven by strong performances in the Industrials and Financials sectors. As investors navigate these shifting landscapes, identifying undervalued stocks like Domino's Pizza Enterprises and others could offer potential opportunities for those seeking value in a buoyant yet selective market environment.Top 10 Undervalued Stocks Based On Cash Flows In Australia. Domino's Pizza Enterprises is trading at A$33.35, significantly below its estimated fair value of A$53.18, indicating potential undervaluation based on cash flows. Although revenue growth is modest at 3.8% annually, earnings are expected to grow significantly by 24.1% per year over the next three years, outpacing the broader Australian market's growth rate of 12.3%. However, a high debt level and an unsustainable dividend coverage may pose challenges despite strong profit forecasts and a high future return on equity of 26.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dominos-pizza-enterprises-2-other-080232676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DMP.AU","BK4139","BK4532","BK4585","BK4524","MSB.AU","BK4209","DPZ","BK4588","MESO","NCK.AU"],"gpt_icon":0},{"id":"2510694533","title":"Cynata Therapeutics' Drug Candidate Could See Pricing Revision Following Mesoblast's Ryoncil Launch, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2510694533","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510694533?lang=en_us&edition=fundamental","pubTime":"2025-02-12 07:11","pubTimestamp":1739315479,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics'  lead asset, CYP-001, could see an upward revision in its pricing assumptions if the launch of Mesoblast's  Ryoncil sets a high market precedent, according to a Feb.10 note by Euroz Hartleys.Based on estimates, Ryoncil could be priced between $500,000 and over US$1 million per patient.Given that Ryoncil is the first US Food and Drug Administration-approved mesenchymal stem cell  therapy, its pricing may influence similar treatments, including CYP-001, Euroz added.Euroz Hartleys notes that while CYP-001, is unlikely to match Ryoncil's pricing, a price of $1 million per patient for Ryoncil could prompt an upward revision of CYP-001's current price estimate of $150,000 per patient.It maintained CYP's speculative buy rating and $0.67 price target.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4150","MSB.AU","BK7501","BK7067","BK7508","MSC","BK4575","MESO","CYP.AU","LENZ"],"gpt_icon":0},{"id":"2510332542","title":"Is Mesoblast Limited (MESO) the Best Long Term ASX Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332542","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510332542?lang=en_us&edition=fundamental","pubTime":"2025-02-12 00:56","pubTimestamp":1739292998,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now.In this article, we are going to take a look at where Mesoblast Limited  stands against the other long term ASX stocks.Vanguard believes that Australia's economy remains well-placed to recover gradually in 2025 after the broader economy witnessed its slowest growth in 32 years in 2024 amid sticky inflation and higher interest rates. The investment firm expects modest improvement in economic momentum, courtesy of higher real household incomes as inflation subsides. Furthermore, a rebounding housing market and expectations of rate cuts might also provide some support.The Reserve Bank of Australia  kept the policy rate target unchanged at 4.35% on December 10. However, the bank noted that it continues to see signs of inflation moving sustainably towards the target. That being said, Vanguard expects that RBA will remain patient and that a tight labor market is expected to keep RBA from initiating rate cuts until Q2 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-limited-meso-best-long-165638920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVIW.SI","PSQ","LU1815336091.USD","USAW.SI","RBA","LU2098885051.SGD","SQQQ","QID","USJW.SI","BK4137","MESO","QLD","LU0757428866.USD","LU1303367103.USD","TQQQ","NQmain","MSB.AU",".IXIC","MNQmain","BK4139","TSYW.SI"],"gpt_icon":1},{"id":"2509420507","title":"Mesoblast Price Target Raised to $24.00/Share From $15.00 by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2509420507","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509420507?lang=en_us&edition=fundamental","pubTime":"2025-02-07 23:01","pubTimestamp":1738940460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MESO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 07, 2025 10:01 ET (15:01 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","MSB.AU"],"gpt_icon":0},{"id":"2509786731","title":"Mesoblast's Largest Shareholder Raises Stake to Over 19%; Mesoblast Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509786731","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509786731?lang=en_us&edition=fundamental","pubTime":"2025-02-07 08:07","pubTimestamp":1738886843,"startTime":"0","endTime":"0","summary":"Mesoblast's (ASX:MSB) largest shareholder Gregory George and G to the Fourth Investments raised their stake in the company to 19.13% from 18.10%, according to a Friday filing with the Australian bourse.The company's shares were up 3% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO","MSB.AU","BK4139","XJO.AU","BK7067","XAO.AU","XKO.AU","BK7501","BK7508","BK4141","MMAT"],"gpt_icon":0},{"id":"2509929746","title":"5 ASX All Ords shares upgraded to 'strong buy' consensus ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=2509929746","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509929746?lang=en_us&edition=fundamental","pubTime":"2025-02-06 12:02","pubTimestamp":1738814543,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ords (ASX: XAO) shares are up 1.04% during a great day for the Aussie share market.  The All Ords enjoyed strong momentum in January, with the index lifting an impressive 4.38%. Here are f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/06/5-asx-all-ords-shares-upgraded-to-strong-buy-consensus-ratings/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CSL.AU","BK7151","REIT","BK4150","CHN.AU","MSC","BK7083","ASK.AU","BK7508","MSB.AU","REIT.AU","XAO.AU","BK7501","BK7067","BK7511","BK7095","BOE.AU","BK4575"],"gpt_icon":0},{"id":"2509725981","title":"BRIEF-Mesoblast Ltd Files Prospectus Relates To Offer And Sale Of Up To 34.7 Million Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2509725981","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509725981?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:04","pubTimestamp":1738789479,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Ltd Files Prospectus Relates To Offer And Sale Of Up To 34.7 Million Ordinary SharesFeb 5  - Mesoblast Ltd MSB.AX:MESOBLAST LTD FILES PROSPECTUS RELATES TO OFFER AND SALE FROM TIME TO TIME BY THE SHAREHOLDERS OF UP TO 34.7 MILLION ORDINARY SHARESSource text: [ID:n0001213900-25-010524]Further company coverage: MSB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW21S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK4139","BK7501","MESO","MSB.AU"],"gpt_icon":0},{"id":"2509256086","title":"Mesoblast Ltd Files Prospectus Relates to Offer and Sale From Time to Time by the Shareholders of up to 34.7 Mln Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2509256086","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509256086?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:03","pubTimestamp":1738789397,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW21S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7501","BK7508","MSB.AU","MESO","BK7067"],"gpt_icon":0}],"pageSize":16,"totalPage":10,"pageCount":2,"totalSize":160}]}}